Premium
Dose‐related healing of duodenal ulcer with the proton pump inhibitor lansoprazole
Author(s) -
LONDONG W.,
BARTH H.,
DAMMANN H. G.,
HENGELS K. J.,
KLEINERT R.,
MÜLLER P.,
ROHDE H.,
SIMON B.
Publication year - 1991
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1991.tb00025.x
Subject(s) - lansoprazole , ranitidine , medicine , gastroenterology , proton pump inhibitor , gastric acid , pharmacology , omeprazole , stomach
SUMMARY Lansoprazole (AG 1749) is a novel substituted benzimidazole which inhibits gastric acid secretion by blocking H + , K + ‐ATPase. This randomized, double‐blind multicentre trial studied the dose–response relationship of lansoprazole on ulcer healing and compared it with ranitidine in 314 out‐patients with endoscopically assessed, symptomatic duodenal ulcer. Cumulative healing rates with Lansoprazole 7.5, 15, and 30 mg o.m. were 48, 59, and 74% at 2 weeks and 75, 84, and 95 % at 4 weeks, respectively (intention‐to‐treat); the difference of the healing rates between 7.5 and 30 mg groups was significant ( P < 0.001). Corresponding healing rates for 300 mg ranitidine nocte were 51 and 89 %. Pain relief was similar in all treatment groups. Lansoprazole was well tolerated. During a follow‐up of 6 months relapse rates after lansoprazole 7.5, 15, and 30 mg were 21, 29, and 22%, respectively; the relapse rate after ranitidine 300 mg was 20%. In conclusion, lansoprazole provides faster healing of duodenal ulcer than ranitidine and a similar relapse pattern. For further trials in peptic ulcer disease a daily dose of lansoprazole 30 mg o.m. is recommended.